Desmoid tumors: old and new drugs for a rare and challenging disease
There has been a paradigm shift in the treatment strategy for patients with desmoid tumor toward less invasive management using systemic therapies. In addition to older drugs, such as conventional chemotherapy and tyrosine kinase inhibitors, the newest class of medical agents—the gamma secretase inh...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) Editorial |
| Language: | English |
| Published: |
1 January 2025
|
| In: |
Cancer
Year: 2025, Volume: 131, Issue: 1, Pages: 1-2 |
| ISSN: | 1097-0142 |
| DOI: | 10.1002/cncr.35603 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/cncr.35603 Verlag, lizenzpflichtig, Volltext: http://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.35603 
|
| Author Notes: | Bernd Kasper |
| Summary: | There has been a paradigm shift in the treatment strategy for patients with desmoid tumor toward less invasive management using systemic therapies. In addition to older drugs, such as conventional chemotherapy and tyrosine kinase inhibitors, the newest class of medical agents—the gamma secretase inhibitors—have been included in the treatment armamentarium for patients with desmoid tumor, as nicely depicted in the latest consensus guideline from The Desmoid Tumor Working Group. |
|---|---|
| Item Description: | Erstmals veröffentlicht: 15. November 2024 Gesehen am 08.05.2025 |
| Physical Description: | Online Resource |
| ISSN: | 1097-0142 |
| DOI: | 10.1002/cncr.35603 |